Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7952 results

Sort By:

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Study ID: NCT04471727
Start Date: 2020-12-14
End Date: 2027-11-17
Study Type

Interventional

Study Phase

Phase2

No. of Participants

232

Intervention / Treatment

Gokatamig

Atezolizumab

Ifinatamab Deruxtecan (I-DXd)

Sponsor

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Source: clinicaltrials.gov

Share:
Add to list

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Study ID: NCT03065062
Start Date: 2017-02-28
End Date: 2026-01-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

96

Intervention / Treatment

Palbociclib

Hydropower

Sponsor

Dana-Farber Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Study ID: NCT05504291
Start Date: 2022-11-04
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

26

Intervention / Treatment

Biospecimen Collection

Carboplatin

Etoposide

Examination Under Anesthesia

Magnetic Resonance Imaging

Melphalan

Ultrasound Biomicroscopy

Vincristine

Sponsor

Children's Oncology Group

Source: clinicaltrials.gov

Share:
Add to list

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Study ID: NCT03704662
Start Date: 2018-10-22
End Date: 2030-09-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

102

Intervention / Treatment

Stereotactic Body Radiation Therapy

Preoperative Fractionated Radiation Therapy and Chemotherapy

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Study ID: NCT03214562
Start Date: 2017-09-26
End Date: 2025-09-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

116

Intervention / Treatment

Cytarabine

Filgrastim

Fludarabine

Again

Freak

Venetoclax

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Study ID: NCT03904862
Start Date: 2019-07-25
End Date: 2030-02-21
Study Type

Interventional

Study Phase

Phase2

No. of Participants

66

Intervention / Treatment

CX 4945

Sponsor

Pediatric Brain Tumor Consortium

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors

Study ID: NCT05932862
Start Date: 2024-04-03
End Date: 2029-08-03
Study Type

Interventional

Study Phase

Phase1

No. of Participants

425

Intervention / Treatment

Calculate 09 (hear 091)

Flapberry

Sponsor

EXELAXIS

Source: clinicaltrials.gov

Share:
Add to list

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Study ID: NCT06928662
Start Date: 2025-09-01
End Date: 2028-03-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

36

Intervention / Treatment

Decitabine

Bone Marrow Aspiration

Bone Marrow Biopsy

Chest Radiography

Cytarabine

Echocardiography Test

Filgrastim

Fludarabine

Hematopoietic Cell Transplantation

Again

Multigated Acquisition Scan

Pheresis

Total-Body Irradiation

Biospecimen Collection

Sponsor

Fred Hutchinson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Study ID: NCT03520491
Start Date: 2018-04-25
End Date: 2026-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Nivolumab

Ipilimumab

Radical cystectomy

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Study ID: NCT06824662
Start Date: 2025-05-01
End Date: 2027-05-01
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

30

Intervention / Treatment

Quisinostat

Sponsor

Nad

Source: clinicaltrials.gov

Share:
Add to list